Neurocrine Biosciences | NBIX - Stock


Neurocrine Biosciences reported $64.5M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Repligen USD 179.26M 8.8M Mar/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026